Haemonetics Corporation (HAE)

Payables turnover

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Cost of revenue (ttm) US$ in thousands 1,140,747 1,090,469 1,052,482 1,022,423 995,675 974,344 938,969 901,797 913,230 907,672 887,138 857,275 811,111 811,195 848,731 891,313 963,513 965,320 948,502 941,885
Payables US$ in thousands 73,358 56,845 80,160 78,134 63,929 63,769 61,484 57,907 58,371 51,175 44,969 49,131 50,293 42,979 49,071 48,459 50,730 52,298 57,449 60,792
Payables turnover 15.55 19.18 13.13 13.09 15.57 15.28 15.27 15.57 15.65 17.74 19.73 17.45 16.13 18.87 17.30 18.39 18.99 18.46 16.51 15.49

March 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $1,140,747K ÷ $73,358K
= 15.55

The payables turnover ratio of Haemonetics Corporation over the last 20 quarters has varied between 13.09 and 19.73, indicating differences in how quickly the company is able to pay off its accounts payable.

A higher payables turnover ratio suggests that the company is paying off its creditors more quickly, which can be a favorable sign of strong liquidity and efficient management of working capital. Conversely, a lower payables turnover ratio may indicate that the company is taking longer to settle its payables, which could potentially strain its cash flow and relationships with suppliers.

Analyzing the trend of Haemonetics Corporation's payables turnover ratio over time, we observe fluctuations in the ratio, indicating changes in the company's ability to manage its accounts payable efficiently. It is essential to consider the reasons behind these fluctuations, such as changes in payment terms, purchasing practices, or supplier relationships, to gain a deeper understanding of the company's financial health and liquidity management.


Peer comparison

Mar 31, 2024